Neuroendocrine Tumor Treatment Market, By Drug Class (Somatostatin Analogs, Chemotherapy, Targeted Therapy, Immunotherapy, Others), By Indication (Gastrointestinal NET, Lung NET, Pancreatic NET, Others), By Distribution Channel (Hospital Pharmacies, Onlin

Neuroendocrine Tumor Treatment Market, By Drug Class (Somatostatin Analogs, Chemotherapy, Targeted Therapy, Immunotherapy, Others), By Indication (Gastrointestinal NET, Lung NET, Pancreatic NET, Others), By Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

Neuroendocrine Tumor Treatment Market, By Drug Class (Somatostatin Analogs, Chemotherapy, Targeted Therapy, Immunotherapy, Others), By Indication (Gastrointestinal NET, Lung NET, Pancreatic NET, Others), By Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

Neuroendocrine tumors (NETs) are a type of cancer that begins in the specialized cells of the body's neuroendocrine system. These cells have traits of both hormone-producing endocrine cells and nerve cells. They are found throughout the body's organs and help control many of the body's functions. NETs are relatively rare and can occur anywhere in the body, but most commonly occur in the lungs, appendix, small intestine, rectum, and pancreas. Neuroendocrine tumors (NETs) can be non-functioning (without symptoms) or functional (with symptoms). Symptoms of functional NETs depend on which hormone is produced, while non-functioning NETs are often detected during imaging tests performed for other reasons. Some NETs are aggressive and fast-growing, while others are slow-growing. The global neuroendocrine tumor treatment market is expected to grow significantly in the coming years. This growth is driven by several factors, including an increase in the prevalence of neuroendocrine tumors, advancements in diagnostic technologies, and the development of new and effective therapies. The treatment of NETs typically involves a combination of surgery, radiation therapy, and medications. The specific type of treatment used is frequently determined by the tumor's form and stage as well as the patient's general condition. In recent years, there has been a significant increase in the development of targeted therapies for NETs. These therapies work by specifically targeting cancer cells, which can help minimize damage to healthy cells.

Market Dynamics

NETs are sometimes called carcinoid tumors, can be symptomatic or asymptomatic and may go undiscovered for years if there are no outward indications or symptoms. NETs are generally characterized by their ability to produce peptides that lead to their syndromes. Thus, increasing research and development activities for the treatment of patients suffering from neuroendocrine tumors is expected to foster market growth over the forecast period. For instance, in March 2022, Amyrt Pharma plc, a commercial stage pharmaceutical company, reported successful bioavailability study for Mycapssa (octreotide capsules) in a planned Phase 3 study in the treatment of carcinoid symptoms associated with neuroendocrine tumor (NET). Furthermore, from the same source above, according to the study, Mycapssa dosages up to 80mg showed the anticipated dose proportionality and bioavailability along with an acceptable safety and tolerability profile.

Key features of the study:

• This report provides an in-depth analysis of the global neuroendocrine tumor treatment market and provides market size (US$ Bn) and Compound Annual Growth Rate (CAGR) for the forecast period (2023-2030), considering 2022 as the base
• It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global neuroendocrine tumor treatment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• The key companies covered as a part of this study include Pfizer Inc, Novartis AG, Ispen, Advanced Accelerator Indications, Tarveda Therapeutics, Progenics Pharmaceuticals, Inc., Hutchison Medipharma Limited, Dauntless Pharmaceuticals Inc., and Exelixis, Inc.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global neuroendocrine tumor treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global neuroendocrine tumor treatment market

Detailed Segmentation:

• By Drug Class:
• Somatostatin Analogs
• Chemotherapy
• Targeted Therapy
• Immunotherapy
• Others
• By Indication:
• Gastrointestinal NET
• Lung NET
• Pancreatic NET
• Others
• By Distribution Channel:
• Hospital Pharmacies
• Online Pharmacies
• Retail Pharmacies
• By Region:
• North America
• Latin America
• Europe
• Asia Pacific
• Middle East
• Africa
• Company Profiles
• Pfizer Inc
• Novartis AG
• Ispen
• Advanced Accelerator Applications
• Tarveda Therapeutics
• Progenics Pharmaceuticals, Inc.
• Hutchison Medipharma Limited
• Dauntless Pharmaceuticals Inc.
• Exelixis, Inc.